General form of registration statement for all companies including face-amount certificate companies

Intangible Assets (Details Narrative) (10-K)

v3.20.2
Intangible Assets (Details Narrative) (10-K) - USD ($)
6 Months Ended 12 Months Ended
Mar. 19, 2018
Oct. 04, 2017
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 23, 2019
Number of shares acquired in exchange for common stock         298,615  
Common stock shares issued 5,039,033 5,039,033 5,514,447   5,486,476 5,525,009  
Common stock shares outstanding 5,039,033 5,039,033 5,514,447   5,486,476 5,525,009 38,404,530
Amortization expense     $ 397,664 $ 397,664 $ 795,328 $ 621,647  
Future amortization expense, thereafter         788,000    
Product Concentration Risk [Member] | Sub License [Member]              
Sales percentage   10.00%          
CoNCERT Pharmaceuticals, Inc [Member]              
Capitalized cost $ 11,038,929            
Recognition of deferred tax liability 3,037,147            
Intangible asset, tax basis $ 1,782            
Number of shares acquired in exchange for common stock 298,615            
Shares acquired price per share $ 26.79            
Fair value of intangible asset received in exchange for common stock $ 8,000,000            
Sublicense royalty percentage 15.00%            
Sales percentage description We will pay the greater of (i) 6% or (ii) 50% of all payment received by us with respect to such sublicencee. We will also pay 15% of any sublicense revenue earned by us for a period equivalent to the royalty term (as defined in the CoNCERT Agreement) until the earliest of (a) our raising $8 million of gross proceeds and (b) CoNCERT being able to sell its shares of our common stock without restrictions pursuant to the terms of the amended Agreement.            
CoNCERT Pharmaceuticals, Inc [Member] | Category 1 [Member] | Maximum [Member]              
Amount of sales limit   $ 100,000,000          
CoNCERT Pharmaceuticals, Inc [Member] | Category 1 [Member] | Product Concentration Risk [Member]              
Sales percentage   4.00%          
CoNCERT Pharmaceuticals, Inc [Member] | Category 2 [Member] | Maximum [Member]              
Amount of sales limit   $ 500,000,000          
CoNCERT Pharmaceuticals, Inc [Member] | Category 2 [Member] | Minimum [Member]              
Amount of sales limit   $ 100,000,000          
CoNCERT Pharmaceuticals, Inc [Member] | Category 2 [Member] | Product Concentration Risk [Member]              
Sales percentage   5.00%          
CoNCERT Pharmaceuticals, Inc [Member] | Category 3 [Member] | Maximum [Member]              
Amount of sales limit   $ 1,000,000,000          
CoNCERT Pharmaceuticals, Inc [Member] | Category 3 [Member] | Minimum [Member]              
Amount of sales limit   $ 500,000,000          
CoNCERT Pharmaceuticals, Inc [Member] | Category 3 [Member] | Product Concentration Risk [Member]              
Sales percentage   6.00%          
CoNCERT Pharmaceuticals, Inc [Member] | Category 4 [Member] | Minimum [Member]              
Amount of sales limit   $ 1,000,000,000          
CoNCERT Pharmaceuticals, Inc [Member] | Category 4 [Member] | Product Concentration Risk [Member]              
Sales percentage   10.00%          
Software License [Member]              
Capitalized cost         $ 20,500